How to buy Lipocine stock (LPCN)

Lipocine is a biotechnology business based in the US. Lipocine shares (LPCN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.72 – a decrease of 3.08% over the previous week. Lipocine employs 17 staff and has a trailing 12-month revenue of around $4.8 million.

Our top picks for where to buy Lipocine stock

Buy Lipocine stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Lipocine stock price (NASDAQ: LPCN)

Use our graph to track the performance of LPCN stocks over time.

Lipocine shares at a glance

• Key figures

Information last updated 2024-12-25.

Latest market close	$4.72
52-week range	$2.74 - $11.79
50-day moving average more info button	$5.15
200-day moving average more info button	$5.40
Wall St. target price	$21.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.75

Is it a good time to buy Lipocine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lipocine price performance over time

Historical closes compared with the close of $4.72 from 2024-12-26

1 week (2024-12-20)	-3.08%
1 month (2024-11-27)	6.07%
3 months (2024-09-27)	6.31%
6 months (2024-06-27)	-39.10%

1 year (2023-12-27)	60.00%
2 years (2022-12-27)	-30.59%
3 years (2021-12-27)	17.68
5 years (2019-12-27)	6.0367

Lipocine financials

Revenue TTM	$4.8 million
Gross profit TTM	$500,000
Return on assets TTM	-22.67%
Return on equity TTM	-34.12%
Profit margin	-176.8%
Book value	$3.83
Market Capitalization more info button	$26.2 million

TTM: trailing 12 months

Lipocine share dividends

We're not expecting Lipocine to pay a dividend over the next 12 months.

Have Lipocine's shares ever split?

Lipocine's shares were split on a 1:17 basis on 11 May 2023 . So if you had owned 17 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lipocine shares – just the quantity. However, indirectly, the new 1600% higher share price could have impacted the market appetite for Lipocine shares which in turn could have impacted Lipocine's share price.

Lipocine share price volatility

Over the last 12 months, Lipocine's shares have ranged in value from as little as $2.74 up to $11.79. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lipocine's is 1.188. This would suggest that Lipocine's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Lipocine overview

Lipocine Inc. , a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah. .

Frequently asked questions

What percentage of Lipocine is owned by insiders or institutions?
Currently 2.906% of Lipocine shares are held by insiders and 9.958% by institutions. How many people work for Lipocine?
Latest data suggests 17 work at Lipocine. When does the fiscal year end for Lipocine?
Lipocine's fiscal year ends in December. Where is Lipocine based?
Lipocine's address is: 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 What is Lipocine's ISIN number?
Lipocine's international securities identification number is: US53630X1046 What is Lipocine's CUSIP number?
Lipocine's Committee on Uniform Securities Identification Procedures number is: 53630X104